Image of Patent Analysis For Medicines And Biotherapeutics In Trials To Treat COVID - 19

Artikel

Patent Analysis For Medicines And Biotherapeutics In Trials To Treat COVID - 19

This report provides an analysis of patents covering medicines in trials to treat COVID -19. The aim of the report is to suport national patent offices and interested parties in developing countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent applications.
The medicines considered for the patent analysis in this report are remdesevir, ruxolitinib and favipiravir, and the biotherapeutics tocilizumab, siltuximab and sarilumab.

Ketersediaan
08013346.048 SRI pPerpustakaan DJKI TangerangTersedia namun tidak untuk dipinjamkan - Tidak Bisa Dipinjam
Informasi Detail
Judul Seri
Reserach Paper
No. Panggil
346.048 SRI p
Penerbit
Geneva : South Centre.,
Deskripsi Fisik
34 hlm
Bahasa
English
ISBN/ISSN
ISSN 1819 -6926
Klasifikasi
346.048
Tipe Isi
text
Tipe Media
other
Tipe Pembawa
-
Edisi
October 2020
Subjek
Patent Analysis
Medicines and Biotherapeutics
Covid - 19
Info Detail Spesifik
This analysis was conducted by Ms. Srividya Ravi, consultant and Patent Agent in India
Pernyataan Tanggungjawab
Versi lain/terkait

Tidak tersedia versi lain

Lampiran Berkas
Tidak Ada Data
Komentar
Anda harus masuk sebelum memberikan komentar